Vast Therapeutics
  • Home
  • About
    • Our Team
    • Scientific Advisory Board
  • Technology
    • Pipeline
    • NO Prodrugs
    • Posters/Presentations
  • Patients
    • Bronchiectasis
    • NTM Lung Disease
    • Cystic Fibrosis
    • Other Targets
  • News
  • Contact
  • Our Team

News

Chuck Swoboda named Vast Therapeutics President & CEO

1/15/2021

 
​Vast Therapeutics, Inc announced that Chuck Swoboda has joined the company as President & CEO.  Prior to joining the company, he spent more than 25 years at Cree, Inc, where he helped lead the company from $6 million in revenue to over $1.6 billion.  During his 16 years as Cree CEO, the company was recognized as one of MIT Technology Review's 50 Smartest Companies and as one of Fast Company's World's 50 Most Innovative Companies.
About Vast Therapeutics, Inc.
Vast Therapeutics, a subsidiary of KNOW Bio, LLC​, a preclinical stage biotechnology company, focused on harnessing nitric oxide's unique properties to treat drug-resistant microbial infections. Vast Therapeutics' patented technology is being used to create a new class of antibiotic alternative compounds that deliver broad-spectrum antimicrobial activity without the risk of developing drug resistance common to traditional antibiotics. More info available at ​www.vasttherapeutics.com.

Comments are closed.


    Archives

    July 2022
    January 2021
    September 2020
    October 2019
    May 2019
    January 2019
    December 2018

    RSS Feed

Vast Therapeutics logo - white

Address

615 Davis Drive, Suite 800
​Morrisville, NC 27560

Contact Us

info@vasttherapeutics.com

Sector

Biopharmaceutical

Industry

​Biotechnology

    Sign Up for Email Alerts

Submit
​Forward-Looking Statement | Privacy | Terms of Use
​Copyright © 2022 Vast Therapeutics - All Rights Reserved
Picture
  • Home
  • About
    • Our Team
    • Scientific Advisory Board
  • Technology
    • Pipeline
    • NO Prodrugs
    • Posters/Presentations
  • Patients
    • Bronchiectasis
    • NTM Lung Disease
    • Cystic Fibrosis
    • Other Targets
  • News
  • Contact
  • Our Team